Groundbreaking Cancer Drug M1231 Enters Clinical Trials
After two decades of development, a groundbreaking antibody drug conjugate, M1231, has entered clinical trials. This innovative treatment, developed by Professor Michael Hust and Professor Stefan Dübel at the Technical University of Brunswick, targets cancer cells with remarkable specificity.
M1231, a bispecific antibody drug conjugate, recognizes two distinct features on cancer cells. This allows it to pinpoint tumor cells precisely, marking a significant advancement in cancer treatment.
The development of M1231 was an 'evolution in a test tube', involving antibody-phage display over a period of over 20 years. Once bound to cancer cells, M1231 activates the body's immune system against the tumor and releases a cancer-fighting active ingredient directly into the tumor, inhibiting its growth.
Currently, clinical trials are underway in Texas and Canada, led by an unidentified pharmaceutical company. The trial, registered as NCT04695847, is investigating the safety of M1231 for patients with metastatic solid tumors, esophageal cancer, and non-small cell lung carcinoma. It is expected to conclude in July 2023.
M1231, a novel antibody-based medication, is showing promise in its early clinical stages. If successful, it could revolutionize cancer treatment by targeting tumors specifically and harnessing the body's immune system.
Read also:
- Inadequate supply of accessible housing overlooks London's disabled community
- Strange discovery in EU: Rabbits found with unusual appendages resembling tentacles on their heads
- Duration of a Travelling Blood Clot: Time Scale Explained
- Fainting versus Seizures: Overlaps, Distinctions, and Proper Responses
